>>Description of the research protocol "LANL"

A Phase I/II study to assess the safety and immunogenicity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic (ASCI) combined with infusions of ex vivo regulatory T cells depleted T lymphocytes in in vivo regulatory T cells depleted patients a
Phase I study| Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : Hémato-onco
Brugmann identifier : LANL
EudraCT identifier : 2011-004144-22


Involved department : Hemato-oncology
Principal investigator : Efira/Nifosi
Sponsor : IJB
Contact : Clinical Research Unit

>This protocol was approved by the ? ethics committee.